Dabigatran Etexilate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dabigatran etexilate: From Anticoagulation to Sclerosing Cholangitis
One-Sentence Summary
Dabigatran etexilate is an oral direct thrombin inhibitor (marketed in Singapore as Pradaxa capsules). The TxGNN model predicts it may be effective for sclerosing cholangitis, but no clinical trials and only 1 loosely related publication (which does not test efficacy in this disease) support this direction. The prediction is currently a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report (the registered indication text is empty) |
| Predicted New Indication | Sclerosing cholangitis |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. From general pharmacology, dabigatran is a direct thrombin (factor IIa) inhibitor, and it is used as an anticoagulant.
The link to sclerosing cholangitis is speculative. Thrombin and PAR signalling may contribute to liver fibrosis and inflammation, but this has not been established for bile duct diseases such as sclerosing cholangitis. The only linked paper concerns drug-drug interaction testing of a different compound, not dabigatran efficacy.
The high TxGNN score (0.998) reflects a pattern found by the knowledge graph model. It is not evidence of clinical benefit. Other top-ranked predictions (for example gout, familial hypercholesterolaemia, and bleeding disorders such as Glanzmann thrombasthenia) also lack plausible mechanisms, which suggests caution about interpreting the scores.
Clinical Trial Evidence
Currently no related clinical trials registered for sclerosing cholangitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36906733 | 2023 | In vitro / DDI evaluation | Clinical Pharmacokinetics | Evaluates cytochrome P450 and transporter-mediated drug interactions of cilofexor, an FXR agonist in development for primary sclerosing cholangitis and NASH. It does not study dabigatran, so it gives no efficacy evidence. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13697P | Pradaxa 75mg, hard capsules | Capsule | Not listed in the compiled data |
| SIN13941P | Pradaxa 150mg, Hard Capsules | Capsule | Not listed in the compiled data |
| SIN13698P | Pradaxa 110 mg, hard capsules | Capsule | Not listed in the compiled data |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): blood coagulation disease, anaemia, macrocytic anaemia, intracerebral haemorrhage. These come from model-derived contraindication links and should be checked against the official package insert.
- Bleeding risk: As an anticoagulant, dabigatran is expected to raise bleeding risk. This matters in cholestatic or advanced liver disease, where coagulation may already be impaired.
Please refer to the package insert for full warnings, contraindications and drug interaction information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials and no efficacy literature for sclerosing cholangitis. The mechanistic link is speculative, and the safety profile of an anticoagulant in a bile duct and liver disease setting is a concern. The package insert warnings and contraindications are also not yet available.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, plus the registered indication text
- Mechanism of action data (for example from DrugBank)
- Preclinical evidence on thrombin/PAR signalling in cholangiopathy models
- A review of bleeding risk and dosing in patients with hepatobiliary disease
- Any registered or published studies of dabigatran in sclerosing cholangitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.